Evidence map›Paper›PMID 36474002›Full record

ArticleJournal of cancer research and clinical oncology2023

IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways.

Liwei Liu, Yan Cheng, Fasu Zhang, Jin Chen, Pingping Tian, Wei Shi, Fei Zhou, Mingya Yang, Min Zhou, Bo Liu

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Liwei LiuCollege of Medical Technology, Anhui Medical College, Hefei, China.
Yan ChengDepartment of Cell Center, The 901th Hospital of PLA Joint Logistic Support Force, Hefei, China.
Fasu ZhangCollege of Medical Technology, Anhui Medical College, Hefei, China.
Jin ChenCollege of Medical Technology, Anhui Medical College, Hefei, China.
Pingping TianCollege of Medical Technology, Anhui Medical College, Hefei, China.
Wei ShiCollege of Medical Technology, Anhui Medical College, Hefei, China.
Fei ZhouCollege of Medical Technology, Anhui Medical College, Hefei, China.
Mingya YangDepartment of Hematology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Min ZhouDepartment of Critical Care, First Affiliated Hospital of University of Science and Technology, Hefei, China.
Bo LiuDepartment of Cell Center, The 901th Hospital of PLA Joint Logistic Support Force, Hefei, China. iul1@163.com.
Anhui Medical University · CN81th Hospital of PLA · CNFirst Affiliated Hospital of Anhui Medical University · CNUniversity of Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effects of cytokines IL-2 and GM-CSF on CXCR3 expression and chemotaxis of CAR-T cells.

backgroundHigh lymphocyte infiltration within the tumor is a basic requirement for good results in tumor immunotherapy; C-X-C motif chemokine receptor 3 (CXCR3) is an important factor for the chemotaxis of lymphocytes to tumor tissues. The tumor microenvironment can exhibit diverse cytokine suppression or promote antitumor immunity. Both interleukin (IL)-2 and granulocyte macrophage colony-stimulating factor (GM-CSF) contribute to the regulation of immunosuppression in the tumor microenvironment. However, the effects of IL-2 and GM-CSF on CXCR3 expression on the T cell surface and its mechanisms are not well understood. Here, we explored the effects of polycytokines on CXCR3 expression in chimeric antigen receptor T cells (CAR-T cells) and on HuH-7 in situ hepatocellular carcinoma. MATERIALS AND

methodsPeripheral blood mononuclear cells (PBMCs) were isolated, followed by purifying using CD3 immunomagnetic beads. Cells were divided into three groups. After 24h of activation using CD3/CD28 antibody, T cells were transfected using lentiviral vector, pGC-SV40-EGFP-GPC3-CAR. Three culture methods were used to amplify the transfected T cells. Method 'A' was to incubate T cells with CD3/CD28 antibody; method 'B' was with CD3/CD28 antibody and IL-2 at a final concentration of 1000 U/ml; method 'C' was with method B in addition of GM-CSF at a final concentration of 1000 U/ml. The phosphorylation of MAPK and PI3K/AKT was determined by western blot. The chemotaxis effect of CAR-T cells on Huh-7 HCCIA in situ was assayed by immunofluorescence and immunohistochemistry.

resultsThe CD3/CD28/IL-2/GM-CSF combination is the most potent for stimulating activated CAR-T cell proliferation and CXCR3 expression in vitro; CD3/CD28/IL-2 induces CAR-T cell expression of CXCR3 through the activation of the PI3K/APK pathway and GM-CSF induces CXCR3 expression in CAR-T cells through the activation of ERK1/2 rather than the p38 MAPK signaling pathway. CAR-GPC3-T cells with high CXCR3 expression showed increased chemotaxis ability to HuH in situ hepatocellular carcinoma, and considerably inhibited the growth of in situ tumors in nude mouse livers.

conclusionA multi-factorial amplification protocol can effectively improve CXCR3 expression on the surface of activated CAR-T cells in vitro, as well as enhance the chemotaxis ability of CAR-T cells in vivo, which significantly inhibit the growth of liver cancer.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsReceptors, Chimeric AntigenReceptors, CXCR3AnimalsCD28 AntigensGranulocyte-Macrophage Colony-Stimulating FactorGranulocytesHumansInterleukin-2Leukocytes, MononuclearMAP Kinase Signaling SystemMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktT-LymphocytesCD28 AntigensGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-2Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, Chimeric AntigenReceptors, CXCR3CAR-T cellsCXCR3GM-CSFIL-2MAPKPI3K/AKT

Identifiers

PMID36474002
PMCPMC11798273
OpenAlexW4311653326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.